Olivier Rascol
#118,253
Most Influential Person Now
Olivier Rascol's AcademicInfluence.com Rankings
Olivier Rascolmedical Degrees
Medical
#1739
World Rank
#2110
Historical Rank
Pharmacology
#160
World Rank
#199
Historical Rank
Neurology
#153
World Rank
#220
Historical Rank
Olivier Rascolphilosophy Degrees
Philosophy
#5244
World Rank
#7996
Historical Rank
Logic
#2553
World Rank
#3564
Historical Rank
Download Badge
Medical Philosophy
Olivier Rascol's Degrees
- Doctorate Medicine Federal University of Toulouse Midi-Pyrénées
- PhD Neuroscience Federal University of Toulouse Midi-Pyrénées
Why Is Olivier Rascol Influential?
(Suggest an Edit or Addition)Olivier Rascol's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results (2008) (4378)
- Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's disease (2004) (1771)
- A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. (2000) (1489)
- Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan (2007) (1068)
- The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease (2011) (1005)
- Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study (2003) (828)
- Depression rating scales in Parkinson's disease: Critique and recommendations (2007) (616)
- Cortical motor reorganization in akinetic patients with Parkinson's disease: a functional MRI study. (2000) (583)
- Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial (2005) (563)
- A double-blind, delayed-start trial of rasagiline in Parkinson's disease. (2009) (526)
- The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease (2011) (493)
- Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS) (2004) (443)
- Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial (2010) (443)
- Priorities in Parkinson's disease research (2011) (391)
- Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial (2014) (381)
- The natural history of multiple system atrophy: a prospective European cohort study (2013) (376)
- Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. (2010) (376)
- Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004 (2005) (371)
- Levodopa in the treatment of Parkinson's disease: Current controversies (2004) (370)
- Prevalence of orthostatic hypotension in Parkinson’s disease (1997) (369)
- Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke (2001) (367)
- Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial (2007) (349)
- Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study (2010) (337)
- Effect of levodopa on pain threshold in Parkinson's disease: A clinical and positron emission tomography study (2005) (317)
- Summary of the recommendations of the EFNS/MDS‐ES review on therapeutic management of Parkinson's disease (2013) (305)
- How much phenotypic variation can be attributed to parkin genotype? (2003) (296)
- Factors predictive of the development of Levodopa‐induced dyskinesia and wearing‐off in Parkinson's disease (2013) (287)
- Treatment interventions for Parkinson's disease: an evidence based assessment (2002) (280)
- Limitations of current Parkinson's disease therapy (2003) (278)
- Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up (2004) (269)
- Chronic pain in Parkinson's disease: The cross‐sectional French DoPaMiP survey (2008) (258)
- Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease (2006) (256)
- Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double‐blind placebo‐controlled trial (2007) (250)
- Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa (2007) (249)
- Supplementary and primary sensory motor area activity in Parkinson's disease. Regional cerebral blood flow changes during finger movements and effects of apomorphine. (1992) (236)
- Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease. (2014) (225)
- Scales to assess sleep impairment in Parkinson's disease: Critique and recommendations (2010) (225)
- LRRK2 in Parkinson disease: challenges of clinical trials (2020) (223)
- Is the Vulnerability of Neurons in the Substantia Nigra of Patients with Parkinson's Disease Related to Their Neuromelanin Content? (1992) (216)
- Presentation, diagnosis, and management of multiple system atrophy in Europe: Final analysis of the European multiple system atrophy registry (2010) (212)
- The ipsilateral cerebellar hemisphere is overactive during hand movements in akinetic parkinsonian patients. (1997) (210)
- Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease (2003) (210)
- Sleep attacks and Parkinson's disease treatment (2000) (208)
- A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes (2011) (207)
- Clozapine improves dyskinesias in Parkinson disease (2004) (204)
- Continuous dopamine-receptor stimulation in early Parkinson's disease (2000) (203)
- Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease (2010) (203)
- Abnormal ocular movements in Parkinson's disease. Evidence for involvement of dopaminergic systems. (1989) (202)
- Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial (2016) (199)
- Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's (2016) (196)
- A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. (1994) (196)
- Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. (2007) (185)
- Ropinirole in the treatment of early Parkinson's disease: A 6‐month interim report of a 5‐year levodopa‐controlled study (1998) (180)
- Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy (1994) (178)
- Milestones in Parkinson's disease therapeutics (2011) (175)
- Multicenter, Open-Label, Trial of Sarizotan in Parkinson Disease Patients With Levodopa-Induced Dyskinesias (the SPLENDID Study) (2004) (172)
- A mutation at codon 279 (N279K) in exon 10 of the Tau gene causes a tauopathy with dementia and supranuclear palsy (1999) (171)
- Adherence to antiparkinson medication in a multicenter European study (2009) (167)
- A genome wide scan for familial high myopia suggests a novel locus on chromosome 7q36 (2002) (164)
- Within-Session and Between-Session Reproducibility of Cerebral Sensorimotor Activation: A Test–Retest Effect Evidenced with Functional Magnetic Resonance Imaging (2001) (162)
- Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial (2018) (161)
- Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia. (1998) (160)
- Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial (2012) (160)
- Development of dyskinesias in a 5‐year trial of ropinirole and L‐dopa (2006) (159)
- Neural Substrate for the Effects of Passive Training on Sensorimotor Cortical Representation: A Study with Functional Magnetic Resonance Imaging in Healthy Subjects (2000) (158)
- A study of salivary secretion in Parkinson's disease. (1999) (158)
- Scales to assess psychosis in Parkinson's disease: Critique and recommendations (2008) (158)
- A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics (2008) (158)
- King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation (2015) (158)
- Longitudinal analysis of impulse control disorders in Parkinson disease (2018) (155)
- Intracellular Ferritin Accumulation in Neural and Extraneural Tissue Characterizes a Neurodegenerative Disease Associated with a Mutation in the Ferritin Light Polypeptide Gene (2004) (155)
- Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease (2001) (154)
- Deficit of verb generation in nondemented patients with Parkinson's disease (2003) (149)
- Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial (2013) (149)
- Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs (2018) (148)
- Mapping of spinocerebellar ataxia 13 to chromosome 19q13.3-q13.4 in a family with autosomal dominant cerebellar ataxia and mental retardation. (2000) (148)
- Dysautonomia rating scales in Parkinson's disease: Sialorrhea, dysphagia, and constipation—Critique and recommendations by movement disorders task force on rating scales for Parkinson's disease (2009) (147)
- Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. (2015) (144)
- Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. (2001) (142)
- Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa. (1994) (142)
- Basal forebrain neurons projecting to the rat frontoparietal cortex: Electrophysiological and pharmacological properties (1986) (141)
- Square wave jerks in parkinsonian syndromes. (1991) (135)
- AFQ056 in Parkinson patients with levodopa‐induced dyskinesia: 13‐week, randomized, dose‐finding study (2013) (130)
- Drug‐induced parkinsonism: a review (1994) (130)
- Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial (2017) (128)
- Drug‐induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France (2011) (126)
- Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study (1998) (126)
- Prediction of cognition in Parkinson's disease with a clinical–genetic score: a longitudinal analysis of nine cohorts (2017) (122)
- A genome-wide association study in multiple system atrophy (2016) (122)
- Placebo influences on dyskinesia in Parkinson's disease (2008) (120)
- Orthostatic Hypotension in Patients with Parkinson’s Disease (2001) (120)
- Selecting deep brain stimulation or infusion therapies in advanced Parkinson’s disease: an evidence-based review (2013) (118)
- Volume and iron content in basal ganglia and thalamus (2009) (114)
- Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. (1996) (114)
- Subthalamic nucleus stimulation reduces abnormal motor cortical overactivity in Parkinson disease. (2004) (112)
- Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinson’s Disease (2010) (111)
- Alterations in the properties of hippocampal pyramidal neurons in the aged rat (1992) (110)
- Chronic administration of selective serotonin reuptake inhibitor (SSRI) paroxetine modulates human motor cortex excitability in healthy subjects (2005) (109)
- A Single Dose of the Serotonin Neurotransmission Agonist Paroxetine Enhances Motor Output: Double-Blind, Placebo-Controlled, fMRI Study in Healthy Subjects (2002) (109)
- Object naming and action-verb generation in Parkinson's disease: A fMRI study (2009) (108)
- Does ageing influence deep brain stimulation outcomes in Parkinson's disease? (2007) (105)
- ABT‐431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease (1999) (101)
- Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. (2014) (101)
- Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations (2010) (99)
- New treatments for levodopa‐induced motor complications (2015) (98)
- Extended-release pramipexole in advanced Parkinson disease (2011) (98)
- Prolonged-release oxycodone–naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial (2015) (96)
- Sleep Attacks and Antiparkinsonian Drugs: A Pilot Prospective Pharmacoepidemiologic Study (2001) (96)
- 123I‐metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders (2009) (96)
- A Phase 2A Trial of the Novel mGluR5‐Negative Allosteric Modulator Dipraglurant for Levodopa‐Induced Dyskinesia in Parkinson's Disease (2016) (93)
- Withdrawing amantadine in dyskinetic patients with Parkinson disease (2014) (92)
- Sleep disruption, daytime somnolence and ‘sleep attacks’ in Parkinson's disease: a clinical survey in PD patients and age‐matched healthy volunteers (2006) (90)
- Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease (1994) (89)
- L-Dopa-induced sedation: a double-blind cross-over controlled study versus triazolam and placebo in healthy volunteers. (1999) (89)
- Randomized, double‐blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease (2010) (89)
- Effect of Side and Rate of Stimulation on Cerebral Blood Flow Changes in Motor Areas during Finger Movements in Humans (1993) (84)
- Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial (2018) (84)
- Cerebral Functional Magnetic Resonance Imaging Activation Modulated by a Single Dose of the Monoamine Neurotransmission Enhancers Fluoxetine and Fenozolone during Hand Sensorimotor Tasks (1999) (83)
- A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease. (1998) (83)
- Prevalence and Pharmacological Factors Associated With Impulse-Control Disorder Symptoms in Patients With Parkinson Disease (2012) (82)
- Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned. (2015) (80)
- Extended-release pramipexole in early Parkinson disease (2011) (80)
- The European Multiple System Atrophy-Study Group (EMSA-SG) (2005) (78)
- Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. (2006) (78)
- Modulation of behavior and cortical motor activity in healthy subjects by a chronic administration of a serotonin enhancer (2005) (77)
- Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial (2015) (76)
- Iron as a therapeutic target for Parkinson's disease (2018) (76)
- Oro‐buccal symptoms (dysphagia, dysarthria, and sialorrhea) in patients with Parkinson’s disease: preliminary analysis from the French COPARK cohort (2012) (76)
- Multimodal MRI assessment of nigro‐striatal pathway in multiple system atrophy and Parkinson disease (2016) (75)
- Which dyskinesia scale best detects treatment response? (2013) (75)
- A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease–Associated Chronic Pain (2016) (74)
- Role of dopamine receptor agonists in the treatment of early Parkinson's disease. (2009) (74)
- Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson's disease (2012) (73)
- Parkinson's disease and local atrophy in subcortical nuclei: insight from shape analysis (2015) (72)
- Unmasking levodopa resistance in Parkinson's disease (2016) (71)
- α2-Adrenoceptor Antagonists (1998) (69)
- Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo‐controlled study (2010) (68)
- Minimal Clinically Important Difference in Parkinson's Disease as Assessed in Pivotal Trials of Pramipexole Extended Release (2014) (68)
- Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine (2018) (68)
- The improvement of movement and speech during rapid eye movement sleep behaviour disorder in multiple system atrophy. (2011) (67)
- Perspectives on recent advances in the understanding and treatment of Parkinson’s disease (2009) (67)
- Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non‐motor symptoms – results of a double‐blind, randomized, placebo‐controlled trial (2015) (64)
- Parkinson's disease and weight loss: A study with anthropometric and nutritional assessment (1992) (64)
- Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia (2016) (62)
- Methylphenidate modulates cerebral post-stroke reorganization (2006) (62)
- Pseudophaeochromocytoma in parkinsonian patient treated with fluoxetine plus selegiline (1993) (62)
- Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight (2008) (62)
- MRI supervised and unsupervised classification of Parkinson's disease and multiple system atrophy (2018) (61)
- Septo-hippocampal neurons in the rat: Further study of their physiological and pharmacological properties (1986) (61)
- Effects of yohimbine on plasma catecholamine levels in orthostatic hypotension related to Parkinson disease or multiple system atrophy. (1993) (61)
- Flunarizine versus Pizotifen: A Double‐Blind Study in the Prophylaxis of Migraine (1986) (60)
- Safety and tolerability of growth hormone therapy in multiple system atrophy: A double‐blind, placebo‐controlled study (2007) (58)
- Nociceptive brain activation in patients with neuropathic pain related to Parkinson's disease. (2013) (57)
- Trial designs used to study neuroprotective therapy in Parkinson's disease (2013) (57)
- Omega-conotoxin GVIA blocks synaptic transmission in the CA1 field of the hippocampus. (1989) (57)
- Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study (2006) (57)
- The Movement Disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension (2011) (56)
- Does fluoxetine aggravate Parkinson's disease? A pilot prospective study (1995) (56)
- Effect of subthalamic deep brain stimulation on pain in Parkinson’s disease (2012) (55)
- The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model (2014) (55)
- Influence of Age, Circadian and Homeostatic Processes on Inhibitory Motor Control: A Go/Nogo Task Study (2012) (55)
- “Disease-modification” trials in Parkinson disease: Target populations, endpoints and study design (2009) (54)
- Pain in Parkinson's disease: facts and uncertainties (2018) (54)
- Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study. (1991) (54)
- Multiple System Atrophy: Recent Developments and Future Perspectives (2019) (53)
- Factors related to orthostatic hypotension in Parkinson's disease. (2012) (53)
- Efficacy and safety of amantadine for the treatment of l-DOPA-induced dyskinesia (2018) (52)
- Falls in ambulatory non-demented patients with Parkinson’s disease (2015) (52)
- Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease. (2015) (52)
- A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up. (1989) (51)
- Dyskinesia: L-dopa-induced and tardive dyskinesia. (2001) (50)
- Medical treatment of levodopa-induced dyskinesias. (2000) (50)
- The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson’s disease (2000) (50)
- Neuroprotection in Parkinson's Disease (1996) (49)
- Comparison of septo-hippocampal with basalo-cortical projection neurons in the rat: An electrophysiological approach (1986) (49)
- Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis. (2015) (48)
- Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6‐month, randomized, placebo‐controlled study (2003) (48)
- Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease (2017) (47)
- New concerns about old drugs: Valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance (2004) (47)
- Skin cancer and Parkinson's disease (2010) (46)
- Normal frontal perfusion in patients with frozen gait (1998) (45)
- Perampanel in Parkinson Disease Fluctuations: A Double-Blind Randomized Trial With Placebo and Entacapone (2012) (45)
- Trial of Cinpanemab in Early Parkinson's Disease. (2022) (45)
- L‐DOPA‐induced dyskinesias, motor fluctuations and health‐related quality of life: the COPARK survey (2017) (44)
- Levodopa monotherapy can induce “sleep attacks” in Parkinson's disease patients (2001) (44)
- The Safety of Ropinirole, a Selective Nonergoline Dopamine Agonist, in Patients with Parkinson's Disease (1998) (43)
- Antivertigo Medications and Drug-Induced Vertigo (1995) (42)
- Rationale for delayed‐start study of pramipexole in Parkinson's disease: The PROUD study (2010) (42)
- A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease. (1992) (42)
- Treatment of Parkinson's disease should begin with a dopamine agonist (1999) (41)
- Selective serotonin reuptake inhibitor paroxetine modulates motor behavior through practice. A double-blind, placebo-controlled, multi-dose study in healthy subjects (2002) (41)
- Atypical parkinsonism and Annonaceae consumption in New Caledonia (2004) (41)
- Subjective sleep dysfunction and insomnia symptoms in Parkinson's disease: Insights from a cross-sectional evaluation of the French CoPark cohort. (2015) (40)
- Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society–European Section. Part I: early (uncomplicated) Parkinson's disease (2006) (40)
- Late (Complicated) Parkinson's Disease (2010) (40)
- New insights into orthostatic hypotension in multiple system atrophy: a European multicentre cohort study (2015) (40)
- Antivertigo medications and drug-induced vertigo. A pharmacological review. (1995) (39)
- Long‐term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open‐label extensions (2019) (39)
- Adverse Drug Reactions to Selegiline: A Review of the French Pharmacovigilance Database (2000) (39)
- A Phase 1 Randomized Trial of Specific Active α‐Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy (2020) (39)
- Clinical and economic analysis of spa therapy in Parkinson's disease (2003) (38)
- Sublingual apomorphine and Parkinson's disease. (1989) (38)
- Efaroxan, an alpha‐2 antagonist, in the treatment of progressive supranuclear palsy (1998) (38)
- Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients (2014) (38)
- Effect of the α2 adrenoreceptor antagonist, idazoxan, on motor disabilities in MPTP-treated monkey (1999) (38)
- Confinement and sleep deprivation effects on propensity to take risks. (2009) (38)
- Lorazepam-induced modifications of saccadic and smooth-pursuit eye movements in humans: attentional and motor factors (2000) (38)
- Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials (2011) (37)
- [Drug-induced parkinsonian syndromes: a 10-year experience at a regional center of pharmaco-vigilance]. (1994) (37)
- Long‐term effects of rasagiline and the natural history of treated Parkinson's disease (2016) (37)
- Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial. (2012) (36)
- Clinical features and disease haplotypes of individuals with the N279K tau gene mutation: a comparison of the pallidopontonigral degeneration kindred and a French family. (2002) (36)
- Double‐blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease (2010) (36)
- Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease (2018) (36)
- Emerging drugs for autonomic dysfunction in Parkinson's disease (2013) (35)
- Glutamate antagonists and Parkinson's disease: A review of clinical data (1997) (35)
- Rotigotine Transdermal Patch A Review of its Use in the Management of Parkinson's Disease (2007) (35)
- Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study. (2008) (34)
- Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease (2016) (33)
- Emerging analgesic drugs for Parkinson's disease (2012) (33)
- Efficacy, safety, and tolerability of overnight switching from immediate‐ to once daily extended‐release pramipexole in early Parkinson's disease (2010) (33)
- Cannabis smoking impairs driving performance on the simulator and real driving: a randomized, double‐blind, placebo‐controlled, crossover trial (2018) (32)
- Young-onset Parkinson disease with and without parkin gene mutations: a fluorodopa F 18 positron emission tomography study. (2003) (32)
- Amitriptyline Treatment in Chronic Drug‐Induced Headache: A Double‐Blind Comparative Pilot Study (2001) (32)
- The management of patients with early Parkinson's disease. (2002) (32)
- Transmission of group II heteronymous pathways is enhanced in rigid lower limb of de novo patients with Parkinson's disease. (2002) (32)
- Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over ("n-of-1") exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson's disease patients. (2013) (31)
- N‐methyl‐D‐aspartate (NMDA) antagonist and Parkinson's disease: A pilot study with dextromethorphan (2004) (31)
- Pressor and bradycardic effects of tacrine and other acetylcholinesterase inhibitors in the rat. (1998) (31)
- Early (Uncomplicated) Parkinson's Disease (2010) (31)
- Disease progression and prognostic factors in multiple system atrophy: A prospective cohort study (2020) (31)
- Cortical motor activation in akinetic schizophrenic patients: A pilot functional MRI study (2004) (30)
- Efficacy and Safety of Extended- Versus Immediate-Release Pramipexole in Japanese Patients With Advanced and L-dopa–Undertreated Parkinson Disease: A Double-Blind, Randomized Trial (2012) (30)
- Drugs associated with restless legs syndrome: a case/noncase study in the French Pharmacovigilance Database. (2012) (30)
- An original pharmacoepidemiological–pharmacodynamic method: application to antipsychotic‐induced movement disorders (2017) (30)
- Multiple system atrophy: A prototypical synucleinopathy for disease-modifying therapeutic strategies (2014) (30)
- Effects of calcium channel agonist and antagonists on calcium‐dependent events in CA1 hippocampal neurons (1991) (29)
- Suggestive association between OPRM1 and impulse control disorders in Parkinson's disease (2018) (29)
- Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients. (1998) (29)
- Do Parkinson’s disease patients disclose their adverse events spontaneously? (2012) (29)
- Rotigotine transdermal delivery for the treatment of Parkinson's disease (2009) (29)
- Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease (2001) (29)
- Defining a minimal clinically relevant difference for the unified Parkinson's rating scale: An important but still unmet need (2006) (28)
- Anticholinergic therapies in the treatment of Parkinson's disease (2002) (28)
- Speech therapy in Parkinson's disease (2002) (28)
- Amantadine in the treatment of Parkinson's disease and other movement disorders (2021) (27)
- A randomized, double‐blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease (1999) (27)
- A Placebo‐Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa‐Induced Dyskinesia (2016) (27)
- Should Dopamine Agonists be Given Early or Late in the Treatment of Parkinson’s Disease? (1984) (27)
- L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach. (1999) (27)
- Safety of rasagiline for the treatment of Parkinson's disease (2011) (27)
- Effect of levodopa on both verbal and motor representations of action in Parkinson’s disease: A fMRI study (2013) (27)
- Safety and Tolerability of Pardoprunox, a New Partial Dopamine Agonist, in a Randomized, Controlled Study of Patients with Advanced Parkinson’s Disease (2009) (26)
- Effects of acute levodopa administration on blood pressure and heart variability in never treated parkinsonians. (1995) (26)
- Clinical phenotype and neuroimaging findings in a French family with hereditary ferritinopathy (FTL498‐499InsTC) (2009) (26)
- P1.203 Immediate vs. delayed-start pramipexole in early Parkinson's disease: the PROUD study (2009) (26)
- A proof‐of‐concept, randomized, placebo‐controlled, multiple cross‐overs (n‐of‐1) study of naftazone in Parkinson’s disease (2012) (26)
- Rasagiline in the pharmacotherapy of Parkinson’s disease – a review (2005) (26)
- Examining the Reserve Hypothesis in Parkinson's Disease: A Longitudinal Study (2019) (25)
- Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease (2014) (25)
- Abnormal vestibuloocular reflex cancellation in multiple system atrophy and progressive supranuclear palsy but not in Parkinson's disease (1995) (25)
- Current Concepts in the Treatment of Multiple System Atrophy (2015) (25)
- Ergoline and non-ergoline derivatives in the treatment of Parkinson’s disease (2006) (25)
- Induction by Dopamine D 1 Receptor Agonist ABT-431 of Dyskinesia Similar to Levodopa in Patients With Parkinson Disease (2001) (24)
- Adverse drug reactions to dopamine agonists: A comparative study in the french pharmacovigilance database (2010) (24)
- The challenge of developing adenosine A2A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant. (2020) (24)
- Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study (2019) (24)
- Patient‐reported convenience of once‐daily versus three‐times‐daily dosing during long‐term studies of pramipexole in early and advanced Parkinson’s disease (2013) (24)
- The safety and efficacy of safinamide mesylate for the treatment of Parkinson’s disease (2016) (24)
- A study of tolerance to apomorphine (1996) (23)
- Cognition and cerebral blood flow in lateralised parkinsonism: lack of functional lateral asymmetries. (1991) (23)
- Spontaneously hypertensive rats cholinergic hyper‐responsiveness: central and peripheral pharmacological mechanisms (1999) (23)
- Dopamine agonists: what is the place of the newer compounds in the treatment of Parkinson's disease? (1999) (23)
- A Pharmacoeconomic Evaluation of Botulinum Toxin in the Treatment of Spasmodic Torticollis (2000) (23)
- Orodispersible sublingual piribedil to abort OFF episodes: A single dose placebo‐controlled, randomized, double‐blind, cross‐over study (2010) (23)
- Fluoxetine in orthostatic hypotension of Parkinson's disease: A clinical and experimental pilot study (1998) (23)
- Longitudinal one-year study of levels and stoichiometry of neurofilament heavy and light chain concentrations in CSF in patients with multiple system atrophy (2009) (22)
- Assessing the risk of a necessary harm (2005) (22)
- Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting (2018) (22)
- Limitations of current Parkinson's disease therapy. Discussion (2003) (22)
- Contrasting Changes in Cortical Activation Induced by Acute High-Frequency Stimulation within the Globus Pallidus in Parkinson's Disease (2009) (22)
- Safety Profile of Opicapone in the Management of Parkinson's Disease. (2019) (22)
- Motor activation in multiple system atrophy and Parkinson disease (2010) (22)
- Migraine attacks induced by subcutaneous apomorphine in two migrainous parkinsonian patients. (1990) (21)
- Assessment of the Scopa-Aut questionnaire in multiple system atrophy: relation to UMSARS scores and progression over time. (2012) (21)
- Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study. (2019) (21)
- Dual-release formulation, a novel principle in l-dopa treatment of Parkinson’s disease (2001) (21)
- A pilot study of stiripentol, a new anticonvulsant drug, in complex partial seizures uncontrolled by carbamazepine. (1989) (20)
- Subcutaneous apomorphine increases regional cerebral blood flow in parkinsonian patients via peripheral mechanisms. (1991) (20)
- A Double‐Blind, Randomized, Placebo and Active‐Controlled Study of Nebicapone for the Treatment of Motor Fluctuations in Parkinson's Disease (2010) (20)
- [Nephropathy associated with Chinese herbal drugs. 2 cases]. (1994) (20)
- Two weeks of treatment with deprenyl (selegiline) does not prolong l‐dopa effect in parkinsonian patients (1988) (20)
- Hereditary ferritinopathy (2003) (20)
- Dopaminagonists and fibrotic valvular heart disease: Further considerations (2004) (20)
- Impact of Subthalamic Deep Brain Stimulation on Impulse Control Disorders in Parkinson's Disease: A Prospective Study (2020) (20)
- Extended-release carbidopa-levodopa in Parkinson's disease (2013) (20)
- Alpha 2-adrenergic sensitivity in Parkinson's disease. (1989) (20)
- Lack of yohimbine effect on ambulatory blood pressure recording: a double-blind cross-over trial in parkinsonians with orthostatic hypotension. (1993) (19)
- Skin cancers and precancerous lesions in Parkinson's disease patients (2007) (19)
- Amantadine and other antiglutamate agents (2002) (19)
- Rotigotine transdermal patch for the treatment of Parkinson’s Disease (2013) (19)
- Blood pressure and plasma catecholamines in never‐treated parkinsonian patients (1990) (18)
- Pramipexole for the treatment of early Parkinson’s disease (2011) (18)
- Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs (2018) (18)
- Atropinic (Anticholinergic) Burden in Parkinson's Disease (2016) (18)
- A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients. (1996) (18)
- Activation of Regional Cerebral Blood Flow by a Memorization Task in Early Parkinson's Disease Patients and Normal Subjects (1994) (18)
- Pandemrix°, (H1N1)v influenza and reported cases of narcolepsy. (2011) (18)
- Experience of care for Parkinson's disease in European countries: a survey by the European Parkinson's Disease Association (2018) (18)
- Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study. (2021) (18)
- Impaired activity of the supplementary motor area in akinetic patients with Parkinson's disease. Improvement by the dopamine agonist apomorphine. (1993) (17)
- Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease (2000) (17)
- Treatment of depression in idiopathic Parkinson's disease (2002) (17)
- Trimetazidine: A new cause for drug‐induced parkinsonism? (2005) (17)
- Espresso Coffee for the Treatment of Somnolence in Parkinson’s Disease: Results of n-of-1 Trials (2016) (17)
- Safety, Tolerability and Anti-Dyskinetic Efficacy of Dipraglurant, a Novel mGluR5 Negative Allosteric Modulator (NAM) in Parkinson's Disease (PD) Patients with Levodopa-Induced Dyskinesia (LID) (S23.004) (2013) (17)
- Combined cardiovascular and sweating autonomic testing to differentiate multiple system atrophy from Parkinson's disease (2017) (17)
- The delayed-start study in Parkinson disease (2010) (16)
- Cardiovascular effects of apomorphine in humans: evidence for peripheral mechanisms. (1986) (16)
- Characterization of Burning Mouth Syndrome in Patients with Parkinson's Disease. (2016) (16)
- Lacrimation in Parkinson's disease. (1994) (15)
- Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson’s Disease: A Randomized, Placebo-Controlled, Phase 1 Study (2021) (15)
- Assessment of quality of life with the multiple system atrophy health‐related quality of life scale (2012) (15)
- A French survey on the lockdown consequences of COVID-19 pandemic in Parkinson's disease. The ERCOPARK study (2021) (15)
- How to diagnose parkinsonian central pain? (2019) (15)
- Dopamine transporter imaging for the diagnosis of multiple system atrophy cerebellar type. (2019) (15)
- Dopamine agonists. Their role in the management of Parkinson's disease. (2001) (15)
- Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. (2018) (15)
- New Directions in the Drug Treatment of Parkinson’s Disease (1996) (15)
- Rotigotine transdermal delivery for the treatment of Parkinson's disease. (2009) (14)
- A totally data-driven whole-brain multimodal pipeline for the discrimination of Parkinson's disease, multiple system atrophy and healthy control (2019) (14)
- The Unified Multiple System Atrophy Rating Scale: Intrarater reliability (2012) (14)
- Alopecia: an adverse effect of bromocriptine. (1993) (14)
- Clinical Rating Scales for Urinary Symptoms in Parkinson Disease: Critique and Recommendations (2018) (14)
- Pergolide: Multiple-Dose Pharmacokinetics in Patients with Mild to Moderate Parkinson Disease (2005) (14)
- A single report of hemiplegic arm stretching related to yawning: further investigation using apomorphine administration (1994) (14)
- Faculty Opinions recommendation of Central pain modulation after subthalamic nucleus stimulation: A crossover randomized trial. (2013) (14)
- Cardiovascular effects of central injection of acetylcholine in anaesthetized dogs: a role for vasopressin release (1990) (14)
- Deep Brain Stimulation for Parkinson’s Disease: Correlation between Intraoperative Subthalamic Nucleus Neurophysiology and Most Effective Contacts (2004) (14)
- Drugs to treat dementia and psychosis (2002) (14)
- Pain relief with intracameral mepivacaine during phacoemulsification (2000) (14)
- Redefining the strategy for the use of COMT inhibitors in Parkinson’s disease: the role of opicapone (2021) (13)
- MAO‐B inhibitors for the treatment of Parkinson's disease (2002) (13)
- Differential effects of M1 and M2 muscarinic drugs on septohippocampal, hippocampal and cortical neurons in the rat (1988) (13)
- Current Status of Dopamine Agonists in Parkinson’s Disease Management (1993) (13)
- Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged‐release (2011) (13)
- Safety of entacapone and apomorphine coadministration in levodopa‐treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double‐blind, placebo‐controlled, cross‐over study (2004) (13)
- LRP10 in α-synucleinopathies (2018) (13)
- Critical appraisal of clinical trials in multiple system atrophy: Toward better quality (2017) (13)
- Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trial. (2019) (13)
- Monoamine oxidase inhibitors—is it time to up the TEMPO? (2003) (12)
- Phase-3 Clinical Trials of Adjunctive Therapy with Preladenant, an Adenosine 2a Antagonist, in Patients with Parkinson’s Disease (P7.087) (2014) (12)
- Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [11C]PBR28 and Machine Learning Analysis (2021) (12)
- Sublingual apomorphine: a new pharmacological approach in Parkinson's disease? (1995) (12)
- Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson’s Disease: A Pooled Analysis of 8 Phase 2b/3 Trials (2021) (12)
- Central cardiovascular effects of acetylcholine in the conscious dog (1995) (12)
- Antiparkinsonian drugs (2023) (12)
- Lack of correlation between plasma levels of amitriptyline (and nortriptyline) and clinical improvement of chronic pain of peripheral neurologic origin. (1987) (12)
- Success rate, efficacy, and safety/tolerability of overnight switching from immediate‐ to extended‐release pramipexole in advanced Parkinson's disease (2013) (12)
- Orphan drug clinical development. (2020) (12)
- A genome wide scan for familial high myopia suggests a novel locus on chromosome 7 q 36 (2002) (11)
- A study of dopaminergic sensitivity in Parkinson's disease: comparison in "de novo" and levodopa-treated patients. (1996) (11)
- Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson’s disease treated with L-DOPA (2017) (11)
- French consensus procedure for assessing cognitive function in Parkinson's disease. (2016) (11)
- CALCIUM ANTAGONISTS AND THE VESTIBULAR SYSTEM: A CRITICAL REVIEW OF FLUNARIZINE AS AN ANTIVERTIGO DRUG (1989) (11)
- Dementia with Lewy bodies and Parkinson disease with dementia (2007) (11)
- Modulation of the excitability of septohippocampal terminals in the rat: relation to neuronal discharge rate (1987) (11)
- Autonomic nervous system dysfunction and adrenoceptor regulation in Parkinson's disease. Clinical and pharmacological consequences. (1996) (11)
- Naloxone or haloperidol but not yohimbine reverse apomorphine-induced respiratory depression. (1992) (11)
- Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinson’s disease (2016) (11)
- Parkinson disease: Serotonin reuptake inhibitors for depression in PD (2012) (11)
- Ayurveda Medicine for the Treatment of Parkinson's Disease (2013) (10)
- A Randomized, Double‐Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease (2022) (10)
- New perspectives on study designs for evaluating neuroprotection in Parkinson's disease (2017) (10)
- Trial of Deferiprone in Parkinson's Disease. (2022) (10)
- Cerebral autoregulation is preserved in multiple system atrophy: A transcranial Doppler study (2006) (10)
- Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA‐FLUO Trial (2021) (10)
- On‐Demand Therapy for OFF Episodes in Parkinson's Disease (2021) (10)
- The discovery of vasomotor nerves (1996) (10)
- Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases (2019) (10)
- Nonmotor Symptoms Groups in Parkinson's Disease Patients: Results of a Pilot, Exploratory Study (2011) (10)
- Transdermal delivery of dopaminergic agents (2005) (10)
- Challenges and Perspectives in the Management of Late-Stage Parkinson’s Disease (2020) (10)
- A dose‐ranging study of selegiline in patients with Parkinson's disease: Effect on platelet monoamine oxidase activity (1997) (9)
- Disease modifying trials in Alzheimer disease: methodological and statistical issues. (2006) (9)
- LRP10 in α-synucleinopathies (2018) (9)
- Characterization of the central muscarinic cholinoceptors involved in the cholinergic pressor response in anesthetized dogs. (1999) (9)
- Drugs to treat autonomic dysfunction in Parkinson's disease (2002) (9)
- French Parkinson's Disease Genetics Study Group are Y. Agid, (2005) (9)
- Broad white matter impairment in multiple system atrophy (2020) (9)
- Brain 5‐HT1A Receptor Binding in Multiple System Atrophy: An [18F]‐MPPF PET Study (2020) (9)
- Noradrenaline, adrenaline and tyrosine hydroxylase in adrenal medulla from parkinsonian patients. (1988) (9)
- A Cross-Sectional Study on Drug Use in Multiple System Atrophy (2014) (9)
- Vestibulo-ocular reflex in Parkinson's disease and multiple system atrophy. (1993) (8)
- NEOPHROPATHIE ASSOCIEE A DES HERBES CHINOISES : 2 CAS (1994) (8)
- Clinical studies with ropinirole in Parkinson’s disease and RLS (2006) (8)
- [Drug therapy of vertigo]. (1994) (8)
- Parkinson's disease polygenic risk score is not associated with impulse control disorders: A longitudinal study. (2020) (8)
- Parkinson's disease polygenic risk score is not associated with impulse control disorders: A longitudinal study. (2020) (8)
- Mortality and Antipsychotic Drug Use in Elderly Patients With Parkinson Disease in Nursing Homes. (2017) (8)
- Surgical treatment for Parkinson's disease: Deep brain surgery (2002) (8)
- β-Adrenoceptor Drugs and Parkinson’s Disease: A Nationwide Nested Case–Control Study (2020) (8)
- Physical exercise in Parkinson disease: Moving toward more robust evidence? (2013) (8)
- Utilization Patterns of Amantadine in Parkinson’s Disease Patients Enrolled in the French COPARK Study (2020) (8)
- Tamoxifen and the risk of Parkinsonism: a case/non-case study (2018) (8)
- Orthostatic hypotension in Parkinson's disease (2013) (7)
- Sleep attacks in Parkinson's disease (2000) (7)
- Modafinil and pramipexole‐associated somnolence (2001) (7)
- The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II (2021) (7)
- [Arguments in favor of early treatment of Parkinson's disease with dopaminergic agonists]. (1999) (7)
- Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease (2010) (7)
- Distinctive Features of NREM Parasomnia Behaviors in Parkinson’s Disease and Multiple System Atrophy (2015) (7)
- Experimental and clinical approaches to treatment of hypertension by dopamine receptor agonists. (1987) (7)
- Involvement of a pertussis toxin‐sensitive G‐protein in the pharmacological properties of septo‐hippocampal neurones (1989) (7)
- French validation of the questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS). (2019) (7)
- The “Long and Winding Road” of the Disease‐Modifying Effects of Levodopa Has Not Ended Yet (2019) (6)
- Shared Genetics of Multiple System Atrophy and Inflammatory Bowel Disease (2020) (6)
- DA agonists ‐ Ergot derivaties: Cabergoline (2002) (6)
- Phase-3 Clinical Trial of the Adenosine 2a Antagonist Preladenant, Given as Monotherapy, in Patients with Parkinson’s Disease (S7.004) (2014) (6)
- [Neuroleptic malignant-like syndrome following levodopa withdrawal]. (1990) (6)
- Is Motor Side Onset of Parkinson's Disease a Risk Factor for Developing Impulsive‐Compulsive Behavior? A Cross‐Sectional Study (2020) (6)
- Personality Dimensions Are Associated with Quality of Life in Fluctuating Parkinson's Disease Patients (PSYCHO-STIM). (2020) (6)
- Cerebrospinal Fluid Levels of Kininogen‐1 Indicate Early Cognitive Impairment in Parkinson's Disease (2020) (6)
- DA agonists ‐ Non‐Ergot derivaties: Ropinirole (2002) (6)
- [Role of dopaminergic agonists]. (2000) (6)
- Psychosocial counseling in Parkinson's disease (2002) (6)
- Surgical treatment for Parkinson's disease: Neural transplantation (2002) (6)
- Mesulergine (CU 32-085) in the treatment of Parkinson's disease. (1986) (6)
- EFFECT OF APOMORPHINE ON ADRENAL MEDULLARY CATECHOLAMINE LEVELS (1989) (6)
- Therapeutic strategies for Parkinson’s disease: promising agents in early clinical development (2020) (6)
- An Item Response Theory analysis of the Unified Multiple System Atrophy Rating Scale (2021) (6)
- Addressing non-motor impairments in Parkinson's disease: The new version of the UPDRS (2005) (6)
- Parkinson’s Disease Drug Development Since 1999: A Story of Repurposing and Relative Success (2021) (6)
- Reversible myoclonus‐ataxia encephalitis related to anti‐mGLUR1 autoantibodies (2019) (5)
- Validation of the French version of the MSA health-related Quality of Life scale (MSA-QoL). (2013) (5)
- Septohippocampal neurons after intraventricular AF64A administration in rats: An electrophysiological study (1986) (5)
- Opicapone versus placebo in the treatment of Parkinson’s disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial (2022) (5)
- Physical and occupational therapy in Parkinson's disease (2002) (5)
- The Parkinson’s Real-World Impact Assessment (PRISM) Study: A European Survey of the Burden of Parkinson’s Disease in Patients and their Carers (2021) (5)
- Thought disorders among non-demented outpatients with Parkinson’s disease: prevalence and associated factors (2010) (5)
- Personality Related to Quality-of-Life Improvement After Deep Brain Stimulation in Parkinson's Disease (PSYCHO-STIM II). (2021) (5)
- [Effect of bromocriptine on cerebral blood flow in Parkinson's disease]. (1988) (5)
- European survey on national training activities in clinical research (2019) (5)
- [Drugs, Parkinson's disease and parkinsonian syndroms: recent advances in pharmacovigilance]. (2006) (5)
- [Neurodegenerative disease associated with a mutation of codon 279 (N279K) in exon 10 of Tau protein]. (2000) (5)
- Blockade of cholecystokinin-A receptors has no effect on dyskinesias in Parkinson's disease (2001) (4)
- Update on Treatments for Motor Symptom of Pd (4)
- Excessive buccal saliva in patients with Parkinson’s disease of the French COPARK cohort (2020) (4)
- [Comparison of bromocriptine and levodopa as first line treatment of Parkinson's disease: results of a 3-year prospective randomized study]. (1990) (4)
- Jejunal levodopa infusion in Parkinson's disease (2014) (4)
- Naloxone does not prevent apomorphine-induced emesis or hypotension in dogs (1994) (4)
- DA agonists ‐ Non‐Ergot derivaties: Apomorphine (2002) (4)
- [Drug-induced Parkinson syndrome: 10 years of drug vigilance]. (1994) (4)
- Efficacy/safety of opicapone in Parkinson's disease patients according to duration of motor fluctuations: post-hoc analysis of BIPARK-I and II (2020) (4)
- Apomorphine test in parkinsonian syndromes (1990) (4)
- Droxidopa for the treatment of neurogenic orthostatic hypotension and other symptoms of neurodegenerative disorders (2014) (4)
- COMT Inhibitors in the Management of Parkinson’s Disease (2022) (4)
- Efficacy of opicapone in different treatment regimens in Parkinson's disease patients with motor fluctuations (2020) (4)
- Usefulness of OSLER test in Parkinson's disease. (2013) (4)
- Central cardiovascular effects of tacrine in the conscious dog: a role for catecholamines and vasopressin release. (1998) (4)
- Is adrenal medulla involved in the antihypertensive effect of nicardipine? (1988) (4)
- THN 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial (2021) (4)
- Personality dimensions of patients can change during the course of parkinson’s disease (2021) (4)
- Long-term pulmonary safety of inhaled levodopa in parkinson’s disease subjects with motor fluctuations: interim results of a phase 3 study (2018) (3)
- The epsilon (early Parkinson with L-dopa/DDCi and opicapone) study in early Parkinson's disease: Design and rationale of a phase III, double-blind, randomized, placebo-controlled study (2021) (3)
- The Unified Multiple System Atrophy Rating Scale: Status, Critique, and Recommendations (2022) (3)
- Long-Term Pulmonary Safety of Inhaled Levodopa in Parkinson’s Disease Subjects With Motor Fluctuations: a Phase 3 Open-Label Randomized Study (S26.006) (2018) (3)
- Continous dopamine-receptor stimulation in early Parkinson's disease (2000) (3)
- Rhythmical bursting activity and GABAergic mechanisms in the medial septum of normal and pertussis toxin-pretreated rats (2004) (3)
- Descriptive analysis of the French NS-Park registry: Towards a nation-wide Parkinson's disease cohort? (2019) (3)
- Faculty Opinions recommendation of A trial of scheduled deep brain stimulation for Tourette syndrome: moving away from continuous deep brain stimulation paradigms. (2012) (3)
- Adrenal catecholamine concentration after domperidone. (1987) (3)
- CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease. (1990) (3)
- Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies. (2022) (3)
- Ambulatory blood pressure and drug treatment for orthostatic hypotension as predictors of mortality in patients with multiple system atrophy (2021) (3)
- [Management of levodopa-induced dyskinesia]. (2002) (3)
- Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease (2022) (3)
- Flunarizine versus Pizitofen: A Double Blind Study in the Prophylaxis of Migraine (1985) (3)
- [Abnormal diurnal somnolence, "sleep attacks" and antiparkinson drugs]. (2001) (3)
- Distortion of Voiced Obstruents for Differential Diagnosis Between Parkinson's Disease and Multiple System Atrophy (2021) (3)
- Describing complex disease progression using joint latent class models for multivariate longitudinal markers and clinical endpoints (2022) (3)
- Motor activity in parkinsonism and levodopa effect: A PET study (2007) (3)
- Erratum: Levodopa in the treatment of Parkinson's disease: Current controversies (Movement Disorders) (2004)) (2005) (3)
- Neurofilament light levels predict clinical progression and death in multiple system atrophy (2022) (3)
- Adverse drug reactions with Selegiline and Rasagiline compared to Levodopa and Ropinirole: A study in the French Pharmacovigilance Database (2013) (3)
- DA agonists ‐ Ergot derivaties: Lisuride (2002) (3)
- Long-term Efficacy of Inhaled Levodopa in Parkinson’s Disease Subjects With Motor Fluctuations: a Phase 3 Open-Label Randomized Study (S26.008) (2018) (3)
- 1.062 MOOD AND BEHAVIOURAL EVALUATION IN PARKINSON'S DISEASE — VALIDATION OF A NEW SCALE (2012) (3)
- New version of the UPDRS: Development methods and working document for field testing (2005) (3)
- Opicapone as an Add-on to Levodopa in Patients with Parkinson’s Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial (2022) (2)
- Switching entacapone ‘non-responders’ to open-label opicapone: Change in absolute off-time following the 1-year extension BIPARK-I study (2019) (2)
- Clinimetric testing of the new UPDRS (MDS-UPDRS) vs. original version (2007) (2)
- Leucine-Rich Glioma-Inactivated 1 Encephalitis: Broadening the Sphere (2019) (2)
- Leucine-Rich Glioma-Inactivated 1 Encephalitis: Broadening the Sphere (2019) (2)
- [Effect of verapamil independent of its calcium channel antagonist action on hippocampal pyramidal neurons in rats]. (1990) (2)
- European survey on national harmonization in clinical research (2020) (2)
- [Central dopaminergic D1 agonists and treatment of Parkinson disease]. (1997) (2)
- CVT-301 for Parkinson's disease: dose and effect size issues (2019) (2)
- P2.159 Efflcacy and safety of once-daily (qd) pramipexole extended-release for advanced Parkinson's disease (2009) (2)
- Long-term efficacy of inhaled levodopa in Parkinson’s disease subjects with motor fluctuations: Interim results of a phase 3 study (2018) (2)
- Pharmacological Insights into Levodopa‐induced Motor Fluctuations in Patients with Parkinson's Disease (2016) (2)
- Cleopatra-PD: Clinical efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease (2007) (2)
- Adoption (early levodopa with opicapone in Parkinson's patients with motor fluctuations) study in Parkinson's disease: Design and rationale of a randomized prospective, open-label exploratory trial (2021) (2)
- Incidence of treatment-emergent adverse events in Parkinson's disease patients according to baseline disease severity: Post-hoc analysis from double-blind combined BIPARK-I and II data (2019) (2)
- ROPINIROLE - A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF EFFICACY AND SAFETY AS ADJUNCT THERAPY IN PARKINSONIAN-PATIENTS WITH ON OFF FLUCTUATIONS (1993) (2)
- AETIONOMY, a Cross-Sectional Study Aimed at validating a new taxonomy of Neurodegenerative Diseases: Study design and subject characteristics (2019) (2)
- [Movement disorders of drug origin]. (1997) (2)
- 2.262 Adherence to antiparkinson medication in a multi-centre European study. (2007) (2)
- Safety and tolerability of growth-hormone therapy in multiple system atrophy (2007) (2)
- Haplotype-phenotype correlations in kindreds with the N279K mutation in the tau gene. (2004) (2)
- PRODEST study: depressive symptoms in Parkinson's disease (2007) (2)
- Joint models for the longitudinal analysis of measurement scales in the presence of informative dropout. (2022) (2)
- Opicapone as a levodopa sparing agent: Pooled analysis of BIPARK-I and II double-blind trials (2019) (2)
- A comparative study of rasagiline versus placebo or entacapone as adjunt to levodopa in Parkinson's disease (PD) patients with motor fluctuations (the LARGO Study). (2004) (2)
- Post-hoc Analyses of Phase-3 Data with Preladenant, an Adenosine 2a Antagonist, in Patients with Parkinson’s Disease (P7.088) (2014) (2)
- Clinical Trials for Motor Complications in Parkinson’s Disease (2021) (2)
- Endogenous central cholinergic systems and baroreflex modulation in the conscious dog (1998) (2)
- [Movement disorders induced by drugs: experience at a pharmaco-vigilance center over five years]. (1995) (2)
- The Treatment of Early Parkinson's Disease (2008) (2)
- The management of patients with early Parkinson's disease. (2003) (2)
- NS 2330, a DA reuptake inhibitor, in levodopa-treated patients with Parkinson's disease and motor fluctuations: The Phase II ADVANS study (2006) (2)
- Efficacy of opicapone in patients with Parkinson's disease with levodopa dose reduction: a pooled post-hoc analysis of BIPARK-I and II (2020) (2)
- Efficacy of opicapone in Parkinson’s disease patients according to baseline pramipexole use: A post-hoc analysis from combined BIPARK-I and II (2019) (1)
- BouNDless: An active-controlled, randomised, double-blind, double-dummy trial of continuous subcutaneous infusion of levodopa/carbidopa with ND0612 in patients with Parkinson's disease (2020) (1)
- What strategy should France implement for H2020? (2015) (1)
- [Bromocriptine versus levodopa in the early treatment of Parkinson's disease. 1st results after 2 years]. (1988) (1)
- Olivier Diagnosis and treatment of orthostatic hypotension in Parkinson ' s disease (2013) (1)
- Efficacy of opicapone in Parkinson’s disease patients according to baseline rasagiline use: A post-hoc analysis from combined BIPARK-I and II (2019) (1)
- Parkinson disease: Can a new trial end controversy over when to use levodopa? (2014) (1)
- DA agonists ‐ Non‐Ergot derivaties: Piribedil (2002) (1)
- DA agonists ‐ Non‐Ergot derivaties: Pramipexole (2002) (1)
- Influence of disease severity in the efficacy response of Parkinson's disease patients with motor fluctuations: Post-hoc analysis from combined BIPARK-I and II (2019) (1)
- Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinson’s disease (2019) (1)
- Effect of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: Parkinson’s disease questionnaire (PDQ-39) analysis from the BIPARK-I double-blind experience (2019) (1)
- 2.280 RELATIONSHIP BETWEEN POLYPHARMACY AND FREQUENCY OF ADVERSE EVENTS TO ANTIPARKINSONIAN DRUGS: A PRELIMINARY STUDY (2012) (1)
- [Treatments in the early stage of Parkinson disease]. (2008) (1)
- Off-time Treatment Options for Parkinson’s Disease (2023) (1)
- Two-year results of the REGAIN study, a placebo-controlled trial with the non-ergot dopamine agonist piribedil as early treatment of Parkinson's disease (PD) (2005) (1)
- Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: Patient and clinical global impression of change from the BIPARK-I double-blind experience (2019) (1)
- [Clinical pharmacology of dyskinesias induced by L-dopa in Parkinsonian patients]. (1998) (1)
- Sustained efficacy and tolerability of pramipexole extended-release as adjunctive treatment in advanced Parkinson's disease (2010) (1)
- Switching entacapone or placebo to opicapone Open-label: Efficacy results of the BIPARK-I 1-year extension study (2017) (1)
- Prodest - Depressive symptoms in Parkinson's disease: Demographic data (2007) (1)
- 306 CHRONIC PAIN IN PARKINSON'S DISEASE: THE CROSS‐SECTIONAL DOPAMIP SURVEY (2007) (1)
- Rotigotine Transdermal Patch for the Treatment of Restless Legs Syndrome (2014) (1)
- Erratum: Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study (2010) (1)
- Influence of motor fluctuations duration, levodopa dose and duration of use in efficacy responses of Parkinson's disease patients: Post-hoc analysis from combined BIPARK-I and II (2019) (1)
- Challenging diagnosis and treatment decision of a long-history autoantibody-negative autoimmune encephalitis. (2022) (1)
- Incidence of treatment-emergent adverse events in Parkinson's disease patients according to baseline dopamine agonist use: Post-hoc analysis from double-blind combined BIPARK-I and II data (2019) (1)
- Piribedil efficacy in monotherapy (150 to 300 mg/day) in de novo parkinsonian patients: A 6-month intermediate analysis of the 2-year Parkinson-Regain study (2004) (1)
- Leucine-Rich Glioma-Inactivated 1 Encephalitis: Broadening the Sphere. (2019) (1)
- Effect of tropatepine, an anticholinergic drug, on regional cerebral blood flow in patients with Parkinson's disease. (1989) (1)
- Locally activated coagulation induced by a peripheral endovenous catheter. (1991) (1)
- [Disease-modifying therapies in PD]. (2010) (1)
- CORTICAL MOTOR REORGANIZATION IN AKINETIC PARKINSONIAN PATIENTS : A FUNCTIONAL MAGNETIC RESONANCE IMAGING STUDY (1998) (1)
- [Pharmacologic modification of cerebral activity: value of functional neuroimaging]. (2001) (1)
- Alterations in electrochemical skin conductance as a marker of autonomic dysfunction in multiple system atrophy. (2022) (1)
- DA agonists ‐ Ergot derivaties: Dihydroergocryptine (DHEC) (2002) (1)
- Opicapone for Parkinson's disease: clinical evidence and future perspectives. (2021) (1)
- P2.155 Simple overnight switching from immediate- to extended-release pramipexole in early Parkinson's disease at the same daily dosage (2009) (1)
- Dopamine agonists. (2007) (1)
- Results of a Randomized Clinical Trial of Speech After Early Neurostimulation in Parkinson's Disease (2022) (1)
- Nighttime and morning OFF improvements with opicapone in patients with Parkinson's Disease and motor fluctuations: BIPARK-1 and BIPARK-2 pooled subanalyses (2020) (1)
- Do Parkinson’s disease patients disclose their adverse events spontaneously? (2011) (0)
- [Management of levodopa-induced dyskinesia] (2002) (0)
- 2.265 LONG-TERM SAFETY AND SUSTAINED EFFICACY OF EXTENDED-RELEASE PRAMIPEXOLE IN EARLY AND ADVANCED PARKINSON'S DISEASE (2012) (0)
- [Pharmacovigilance of antibiotics. Evaluation by the Midi-Pyrénées Pharmacovigilance Center between 1989 and 1992]. (1994) (0)
- mutation COL 1 A 2 with resolving kyphomelia is caused by a novel A variant of osteogenesis imperfecta type IV (2002) (0)
- Combined CV and sudomotor autonomic testing to differentiate multiple system atrophy from parkinson disease (2015) (0)
- Incidence of treatment-emergent adverse events in Parkinson's disease patients according to race: Post-hoc analysis from double-blind combined BIPARK-I and II data (2019) (0)
- 1.069 SELF ASSESSMENT SCALE FOR DOPAMINE DEPENDENT BEHAVIOURS IN PARKINSON'S DISEASE (2012) (0)
- F1000Prime recommendation of Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. (2013) (0)
- P4-242 Oxidative damage in ferritin-induced neurodegeneration (2004) (0)
- Clinical Trials for in Parkinson’s (2020) (0)
- Clinical and imaging "red flags" for the diagnosis of multiple system atrophy lookalikes. (2023) (0)
- [Antiparkinsonian drug consumption in a University Hospital Center 1981-1990]. (1992) (0)
- Long-term safety and efficacy of transdermal rotigotine in advanced Parkinson's disease (2008) (0)
- COMT Inhibitors in the Management of Parkinson's Disease. (2022) (0)
- Chronic pain and Parkinson’s disease (2009) (0)
- Personality assessment with Temperament and Character Inventory in Parkinson's disease. (2022) (0)
- Baseline Characteristics of Participants of the SPARK Trial, a Phase 2 Study of the anti-alpha-synuclein antibody Cinpanemab (BIIB054) in Parkinson’s Disease (1579) (2020) (0)
- 1.167 PRODEST – Depressive symptoms in Parkinson's disease: Pattern across scales (2007) (0)
- Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach (2023) (0)
- Faculty Opinions recommendation of Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial. (2012) (0)
- Off- and on-time responder post-HOC analyses of pooled opicapone phase III studies (2017) (0)
- Can Dopamine Responsiveness Be Predicted in Parkinson's Disease Without an Acute Administration Test? (2022) (0)
- 2.263 PATIENT-REPORTED CONVENIENCE OF ONCE-DAILY VS TID DOSING DURING LONG-TERM STUDIES OF PRAMIPEXOLE IN EARLY AND ADVANCED PARKINSON'S DISEASE (2012) (0)
- Efficacy of opicapone according to levodopa's duration of use in Parkinson's disease patients with motor fluctuations (2021) (0)
- Medical Treatment of L-Dopa-Induced Dyskinesias (2002) (0)
- 2.249A Efficacy and safety of transdermal lisuride (LIS) in advanced Parkinson's disease (PD) (2007) (0)
- Rotigotine Transdermal System Improves Pain in Patients with Parkinson's Disease: A Post-Hoc Analysis of Patients Reporting Pain in the RECOVER Study (P06.085) (2012) (0)
- OFF/-ON-time changes after switching from entacapone or placebo to opicapone in patients ending the BIPARK-I extension study on opicapone 50-mg (2020) (0)
- 1.501 Relationship between weight, levodopa dose and dyskinesia: Hypothesis testing in ropinole versus levodopa in early Parkinson's disease trial data (2007) (0)
- Switching from double-blind entacapone or placebo to open-label opicapone: change in OFF-/ON-time from patients who ended the 1-year BIPARK-I extension on opicapone 50 mg (2019) (0)
- A comparative study on vowel articulation in Parkinson's disease and multiple system atrophy (2022) (0)
- Chapter 17. Early (Uncomplicated) Parkinson's Disease (2008) (0)
- P3.135 Predictive factors for PD progression – preliminary results of PARKMIP/COPARK cohort after 24-months follow up (2009) (0)
- Direct visual targeting of subthalamic nucleusfor deep brain stimulationin parkinson's disease (2008) (0)
- Intrasubject subcortical quantitative referencing to boost MRI sensitivity to Parkinson's disease (2022) (0)
- [Ambulatory monitoring of blood pressure in orthostatic hypotension of Parkinson disease]. (1993) (0)
- Chapter 18. Late (Complicated) Parkinson's Disease (2008) (0)
- Diagnosis and Treatment of Orthostatic Hypotension in Parkinson's Disease (2013) (0)
- Joint models for the longitudinal analysis of measurement scales in the presence of informative dropout (2021) (0)
- The Role of Parkinson Nurses for Personalizing Care in Parkinson’s Disease: A Systematic Review and Meta-Analysis (2022) (0)
- O.078 Future therapies for Parkinson's disease (2009) (0)
- Dopaminergic Substitution Therapy after Subthalamic Deep Brain Stimulation: An Open Label Randomized Multicentric Controlled Trial (P02.231) (2012) (0)
- Opicapone odds ratio in relative off-time reduction: A post-hoc analysis from combined BIPARK-I and II data (2019) (0)
- Familial dystonia, parkinsonism, ataxia and dementia: what is it? (2008) (0)
- Preoperative REM Sleep Behavior Disorder and Subthalamic Nucleus Deep Brain Stimulation Outcome in Parkinson Disease 1 Year After Surgery (2021) (0)
- The Minimal Clinically Relevant Change in Rating Scales (2012) (0)
- Therapeutic interventions for sleep disorders in Parkinson's disease (2007) (0)
- [Not Available]. (2015) (0)
- 891 Bilateral Subthalamic Nucleus Stimulation in Elderly Patients with Advanced Parkinson's Disease. (2005) (0)
- Rascol , Olivier Emerging drugs for autonomic dysfunction in Parkinson ' s disease (2013) (0)
- Monday, 10 December 200717.00–18.30Afternoon Industry Satellite SymposiumRoom B1.IS.4.3 Efficacy and safety of transdermal lisuride (LIS) in advanced Parkinson's disease (PD) (2007) (0)
- Effect of baseline dyskinesia on safety and efficacy of istradefylline, an A2A receptor antagonist, in Parkinson's disease: 8-study pooled analysis (2020) (0)
- Rotigotine for the Treatment of Advanced Parkinson's Disease (2009) (0)
- Faculty Opinions recommendation of Effect of singing on respiratory function, voice, and mood after quadriplegia: a randomized controlled trial. (2012) (0)
- Study design to assess the effect of opicapone on levodopa pharmacokinetics in different levodopa-optimized treatment regimens in Parkinson's disease patients (2021) (0)
- UMSARS versus laryngoscopy‐based assessment of dysphagia (2023) (0)
- Therapeutic interventions for daytime somnolence in Parkinson's disease (2007) (0)
- Drugs to treat gastrointestinal motility problems (2002) (0)
- Risk of dyskinesia in Parkinson's disease patients who already have developed wearing-off: A secondary analysis of STRIDE-PD study (2013) (0)
- ORF 72 repeat expansions are a rare genetic cause of parkinsonism Running head : C 9 ORF 72 repeat expansion in parkinsonism (2018) (0)
- A genome-wide genetic pleiotropy approach identified shared loci between multiple system atrophy and inflammatory bowel disease (2019) (0)
- Piribedil for symptomatic management of Parkinson's disease (2007) (0)
- Drugs to treat urinary frequency, urgency, and/or urge incontinence (2002) (0)
- DA agonists ‐ Overview (2002) (0)
- Tolcapone of its Use in the Management of (2005) (0)
- Dose-dependent enhancement of motor activation and motor skills by a single dose of paroxetine, a serotonin reuptake inhibitor. A double-blind, placebo-controlled fMRI study in healthy subjects (2001) (0)
- Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Pet Study Using [ 11C ] PBR28 and Machine Learning Enhanced Analysis (2021) (0)
- A motor fluoxetine modulates cerebral motor activation during a motor task in stroke patients (2001) (0)
- Piribedil versus levodopa in early Parkinson's disease (2007) (0)
- Correction to: Excessive buccal saliva in patients with Parkinson’s disease of the French COPARK cohort (2020) (0)
- Effect of drags acting on calcium channels on calcium dependent events in rat CA1 hippocampal neurons (1990) (0)
- Effects of apomorphine on cerebral blood flow and extrapyramidal symptoms in Parkinson's disease (1990) (0)
- , Anne ; Rascol , Olivier Orthostatic hypotension in Parkinson ' s disease (2013) (0)
- The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II (2022) (0)
- [Cerebral hemodynamics and clinical pharmacology in Parkinson disease]. (1988) (0)
- Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinson’s disease (2016) (0)
- Tamoxifen and the risk of Parkinsonism: a case/non-case study (2018) (0)
- Correction to: Off-time Treatment Options for Parkinson’s Disease (2023) (0)
- Treatment of Parkinson’s disease with piribedil: Suggestions for clinical practices (2023) (0)
- 2.284 Impulse-Control Disorders in Parkinson's Disease Patients (2012) (0)
- 2.279 Adverse Events to Antiparkinsonian Medications in Parkinsonian and Non-Parkinsonian Patients (2012) (0)
- Evaluation of Prescription Practices of Domperidone in Parkinson’s Disease: A Cross Sectional Study Among French Neurologists (2020) (0)
- Does papaverine interact with levodopa in Parkinson's disease? (1987) (0)
- No PD Dyskinesia Scale Protects Against Placebo Responses: A Comparison of Multiple Scales (P04.187) (2013) (0)
- P1.11 Dysautonomia Rating Scales in Parkinson's disease: Symptoms of orthostatic hypotension (2009) (0)
- P2.153 Once-daily pramipexole extended-release (ER) demonstrated non-inferiority compared to immediate release (IR) tid dosing in early Parkinson's disease (2009) (0)
- Sustained off-time decrease in patients using pramipexole extended-release as adjunctive treatment in advanced Parkinson's disease (2010) (0)
- Comparisons among responses to pramipexole extended-release as adjunctive treatment in Japanese and non-Japanese studies of advanced Parkinson's disease (2010) (0)
- [Excitability of septo-hippocampal axon terminals: changes as a function of the level of neuronal activity]. (1986) (0)
- Faculty Opinions recommendation of Effect of externally cued training on dynamic stability control during the sit-to-stand task in people with Parkinson disease. (2012) (0)
- DA agonists ‐ Ergot derivaties: Bromocriptine (2002) (0)
- The ocean (opicapone effect on motor fluctuations and associated pain) study in Parkinson's disease: Design and rationale of a randomized double-blind placebo-controlled trial (2021) (0)
- From OFF to ON—Treating OFF Episodes in Parkinson’s Disease (2020) (0)
- REPLY FROM A. KASTNER, E. C. HIRSCH, F. JAVOY‐AGID, O. LEJEUNE, O. RASCOL, AND Y. AGID (1993) (0)
- [Apropos of secondary effects of hydroxyzine]. (1994) (0)
- Impact of current antipsychotic medications on comparative mortality and adverse events in people with Parkinson’s disease psychosis (PDP) (2016) (0)
- Neurodegenerative Traits Detected via 3D CNNs Trained with Simulated Brain MRI: Prediction Supported by Visualization of Discriminant Voxels (2021) (0)
- Heterogeneity of PD-MCI in Candidates to Subthalamic Deep Brain Stimulation: Associated Cortical and Subcortical Modifications. (2022) (0)
- Clinical Features and Disease Haplotypes of Individuals With the N279K tau Gene Mutation (2016) (0)
- Drug-Induced Movement Disorders in Elderly Patients (2014) (0)
- Erratum to Current status of dopamine agonists in Parkinson’s disease (1996) (0)
- Methodological aspects in assessing antidementia drugs. (1996) (0)
- Rasagiline for levodopa-induced motor complications in Parkinson´s disease (2007) (0)
- PANDA: Prolonged release oxycodone/naloxone (OXN PR) for severe Parkinson’s disease (PD)-related pain (2016) (0)
- Chapter 10 Neuroprotection and disease-modification in Parkinson's disease (2010) (0)
- Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease--Rating Scale; French Version (2021) (0)
- F1000Prime recommendation of One-year safety and tolerability profile of pridopidine in patients with Huntington disease. (2013) (0)
- Cardiovascular effects ofcentral injection ofacetylcholine in anaesthetized dogs: arole forvasopressin release (1990) (0)
- Piribedil efficacy in monotherapy (150 to 300 mg/day) in de novo parkinsonian patients: A 6-month planned intermediate of the 2-year Parkinson-regain study (2004) (0)
- MATTERS ARISING (1993) (0)
- Effect of a single dose of fluoxetine (Prozac®) and fenozolone (Ordinator®) on fMRI measurement of brain activity during hand sensorimotor tasks. (1998) (0)
- Characteristics, treatment patterns and disease burden of people with Parkinson's disease in the Parkinson's disease real-world impact assessment (PRISM) study (2020) (0)
- Piribedil for levodopa‐induced complications in Parkinson's disease (2007) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Olivier Rascol?
Olivier Rascol is affiliated with the following schools:
